Abstract
BackgroundSeroprevalence studies have proven an important tool to monitor the progression of the coronavirus disease 2019 (COVID-19) epidemic. We present results of consecutive population-based seroprevalence surveys performed in Denmark in 2020.MethodsInvitation letters including a questionnaire covering symptoms were sent to representatively drawn samples of the population in spring, late summer and autumn/winter of 2020. Blood samples from participants taken at public test-centers were analyzed for total Ig and seroprevalence estimates per population segment calculated and compared to other surveillance parameters.ResultsFrom 34,081 participating individuals (response rate 33%), we obtained seroprevalence estimates increasing from 1.1% (95%CI: 0.7%–1.7) in May to 4.0 % (95%CI: 3.4%–4.7%) in December 2020. By December 2020, 1.5% of the population 12 years and older had tested positive by PCR. Seroprevalence estimates were roughly 3 times higher in those aged 12-29 compared to 65+ and higher in metropolitan municipalities. Among seropositives, loss of taste/smell were the more specific symptoms, 32%-56% did not report any symptoms. In half of seroconverted families, we did not see evidence of transmission between generations. Infected individuals in older age groups were hospitalized several fold more often than in younger.ConclusionsSeroprevalence increased during 2020; younger age groups were primarily infected in the autumn/winter surge. Approximately half were asymptomatically infected. Denmark has a high per capita test rate; roughly two undiagnosed infections of COVID-19 were estimated to occur for each diagnosed case. The epidemic appears to have progressed relatively modestly during 2020 in Denmark.summaryWe describe population-based COVID-19 seroprevalence surveys performed in Denmark in 2020. The seroprevalence increased during the year, particularly in adolescents and young adults, but was overall low. Roughly two undiagnosed cases per PCR-confirmed case were detected by December 2020.
Publisher
Cold Spring Harbor Laboratory
Reference32 articles.
1. Bajema KL , Wiegand RE , Cuffe K , et al. Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020. JAMA Intern Med 2020.
2. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study
3. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study
4. Tunheim G. ; Kran AR, G. ; Steens, A. ; Hungnes O. ; Lund-Johansen, F. ; Tran, T. ; Andersen JT. ;, Vaage J. Seroprevalence of SARS-CoV-2 in the Norwegian population measured in residual sera – analyses collected in April/May 2020 and August 2019. Oslo: Norwegian Institute of Public Health, 2020.
5. Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary;Geroscience,2020
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献